M&A Deal Summary

Artivion Acquires Ascyrus Medical

On September 2, 2020, Artivion acquired medical products company Ascyrus Medical for 200M USD

Acquisition Highlights
  • This is Artivion’s 8th transaction in the Medical Products sector.
  • This is Artivion’s 2nd largest (disclosed) transaction.
  • This is Artivion’s 6th transaction in the United States.
  • This is Artivion’s 1st transaction in Florida.

M&A Deal Summary
Date 2020-09-02
Target Ascyrus Medical
Sector Medical Products
Buyer(s) Artivion
Deal Type Add-on Acquisition
Deal Value 200M USD
Advisor(s) UBS Investment Bank (Financial)
Wyrick Robbins Yates & Ponton LLP (Legal)

Target

Ascyrus Medical

Boca Raton, Florida, United States
Ascyrus Medical LLC is a developer of the Ascyrus Medical Dissection Stent (AMDS™), aortic arch remodeling device used for the treatment of acute Type A aortic dissections. Ascyrus Medical is based in Boca Raton, Florida.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Artivion

Kennesaw, Georgia, United States
Category Company
Founded 1984
Sector Medical Products
Employees1,500
Revenue 354M USD (2023)
DESCRIPTION

Artivion is a manufacturer, processor, and distributor of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. Artivion was incorporated in 1984 and is based in Kennesaw, Georgia.

DEAL STATS #
Overall 8 of 8
Sector (Medical Products) 8 of 8
Type (Add-on Acquisition) 6 of 6
State (Florida) 1 of 1
Country (United States) 6 of 6
Year (2020) 1 of 1
Size (of disclosed) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-11 Endospan

Herzlia, Israel

Endospan Ltd. is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS™ Stent Graft System, the first endovascular off-the shelf system to treat Aortic Arch Disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-29 CryoLife - PerClot Polysaccharide Hemostatic System Certain Assets

Kennesaw, Georgia, United States

CryoLife's PerClot Polysaccharide Hemostatic System Certain Assets are indicated for use in surgical procedures (except neurological and ophthalmic) or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical. CryoLife's PerClot Polysaccharide Hemostatic System Certain Assets are based in Kennesaw, Georgia.

Sell $61M
Mergr

Product

Company

Legal